Hims & Hers Health Inc. (HIMS) 今日盘前股价大涨7.79%，引起了市场的广泛关注。
消息面上，美国食品药品监督管理局（FDA）此前宣布放松对多肽类药物的监管政策，叠加公司与诺和诺德达成合作关系，持续推动股价走强。
此前该股曾在一周内累计大涨逾50%，随后经历回调，本次盘前反弹显示市场围绕FDA多肽政策利好与短线获利回吐之间持续博弈。此外，公司近日披露的持股变动声明及拟议出售证券相关公告，内部人士动向亦受到市场关注。
Hims & Hers Health Inc. (HIMS) 今日盘前股价大涨7.79%，引起了市场的广泛关注。
消息面上，美国食品药品监督管理局（FDA）此前宣布放松对多肽类药物的监管政策，叠加公司与诺和诺德达成合作关系，持续推动股价走强。
此前该股曾在一周内累计大涨逾50%，随后经历回调，本次盘前反弹显示市场围绕FDA多肽政策利好与短线获利回吐之间持续博弈。此外，公司近日披露的持股变动声明及拟议出售证券相关公告，内部人士动向亦受到市场关注。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.